How Do Steroids Affect the Body? Every System They Touch, From Muscle to Mood

Understanding how steroids affect the body means looking beyond muscle growth. Anabolic androgenic steroids interact with androgen receptors in virtually every tissue in the human body, not just skeletal muscle. Your heart, liver, kidneys, brain, skin, blood, bones, reproductive organs and endocrine system all respond to supraphysiological androgen levels, and the response is not always beneficial. This article maps every system that anabolic steroids touch, explains the mechanisms behind each effect, and distinguishes between the changes that reverse after discontinuation and those that may not.

How do steroids affect the musculoskeletal system?

The musculoskeletal effects are the reason people use steroids in the first place, so it is worth understanding exactly what is happening beyond “more protein synthesis.” Supraphysiological androgen levels increase muscle mass through three concurrent mechanisms. First, enhanced gene transcription at the androgen receptor produces more contractile proteins (actin and myosin) within existing muscle fibres, increasing fibre cross-sectional area. Second, satellite cell activation and fusion adds new myonuclei to growing fibres, expanding the nuclear domain and allowing each fibre to sustain a larger volume of contractile protein. Third, the anti-catabolic effect of androgen receptor activation suppresses the ubiquitin-proteasome pathway that would otherwise degrade muscle proteins during periods of metabolic stress.

What is less discussed is the effect on connective tissue. Tendons and ligaments contain androgen receptors, but their adaptation timeline is significantly slower than muscle. Muscle can hypertrophy measurably within weeks of supraphysiological androgen exposure; tendons require months to remodel. This mismatch is why steroid users are vulnerable to tendon injuries during rapid strength gains: the muscle can generate force that the tendon is not yet structurally prepared to transmit. Certain compounds (particularly Nandrolone) stimulate collagen synthesis directly through the androgen receptor in fibroblasts, which partly offsets this mismatch, but the general principle holds: connective tissue lags behind muscle, and training intensity should be managed accordingly.

Bone mineral density increases with androgen exposure. Androgens promote osteoblast activity (bone formation) and inhibit osteoclast activity (bone resorption), which is why testosterone replacement therapy is used clinically to manage osteoporosis in hypogonadal men. However, in younger users whose epiphyseal growth plates have not fully closed (typically under age 25), exogenous androgens can accelerate plate closure, potentially reducing final adult height. This is one of the strongest arguments against steroid use in adolescents and young adults.

How do steroids affect the cardiovascular system?

The cardiovascular system is where the most serious long-term risks of steroid use reside, and it is also where the evidence base has strengthened most dramatically in recent years. A 2025 review in the Journal of Clinical Medicine mapped the molecular mechanisms of cardiovascular toxicity from anabolic steroids across five distinct pathways, each of which operates independently and additively.

The first is atherogenic dyslipidaemia. Anabolic steroids suppress apolipoprotein A-I expression and accelerate HDL catabolism through hepatic lipase upregulation, while simultaneously increasing VLDL and LDL synthesis. The net effect is a dramatic shift in the lipid profile towards atherogenesis: HDL cholesterol drops (by 30% to 70% depending on compound and dose, with oral 17-alpha-alkylated steroids producing the most severe reductions), and LDL cholesterol rises. This shift accelerates the formation of atherosclerotic plaques in coronary and peripheral arteries. The effect is dose-dependent, compound-dependent (oral steroids are worse than injectables for lipids), and reversible on discontinuation, but the atherosclerotic damage accumulated during use may not be.

The second is left ventricular hypertrophy. Androgens directly stimulate androgen receptors on cardiac myocytes, activating the ERK1/2 and mTOR signalling pathways that promote cardiomyocyte growth. They also activate the renin-angiotensin-aldosterone system (RAAS), which promotes cardiac fibrosis through angiotensin II acting on AT-1 receptors. The result is thickening of the left ventricular wall that, in severe cases, can resemble hypertrophic cardiomyopathy on echocardiography. Prospective data from the HAARLEM study demonstrated that this hypertrophy develops during a single cycle and is largely reversible one year after cessation, but studies comparing former long-term users with non-users have found that some degree of concentric hypertrophy persists even years after stopping.

The third is elevated haematocrit. Androgens stimulate erythropoietin production by the kidney, increasing red blood cell mass. At physiological testosterone levels, this is beneficial (it is the mechanism behind testosterone’s use in treating anaemia). At supraphysiological levels, haematocrit can rise above 54%, increasing blood viscosity and the risk of thromboembolic events: deep vein thrombosis, pulmonary embolism, and stroke. Haematocrit monitoring through bloodwork is one of the most important safety measures during steroid use, and therapeutic phlebotomy (blood donation or removal) is the standard intervention if levels become dangerously elevated.

The fourth is hypertension. Water and sodium retention from oestrogenic compounds increases intravascular volume. Sympathetic nervous system activation (particularly from compounds like Trenbolone) increases peripheral vascular resistance. The combination raises blood pressure, and sustained hypertension is a direct cause of left ventricular hypertrophy, kidney damage, and vascular remodelling. Home blood pressure monitoring (morning and evening, before training) is strongly recommended on any cycle.

The fifth is prothrombotic changes. Androgens increase platelet aggregation, stimulate synthesis of procoagulant factors, and alter prostaglandin balance in a direction that favours clotting. Combined with elevated haematocrit and dyslipidaemia, this creates a prothrombotic state that increases the risk of acute cardiovascular events, particularly in users who also have genetic predispositions to clotting disorders.

How do steroids affect the endocrine system?

The endocrine effects of anabolic steroids are the most predictable because they follow directly from the hypothalamic-pituitary-testicular axis (HPTA) feedback loop. Exogenous androgens provide supraphysiological levels of circulating testosterone (or its analogues), which the hypothalamus detects through androgen and oestrogen receptors. In response, it reduces secretion of gonadotropin-releasing hormone (GnRH), which causes the pituitary to reduce secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH). Without LH, the Leydig cells of the testes stop producing endogenous testosterone. Without FSH, the Sertoli cells stop supporting spermatogenesis.

The clinical result is that on any steroid cycle, natural testosterone production drops to near zero, the testes atrophy from disuse (they physically shrink), and sperm production declines dramatically. For most users, these changes are fully reversible after discontinuation and appropriate post-cycle therapy, but recovery takes time (weeks to months depending on cycle length, compounds used, and individual HPTA sensitivity), and a minority of long-term or repeated-cycle users experience persistent hypogonadism that may require lifelong testosterone replacement.

The compounds that produce the most prolonged HPTA suppression are the 19-nor steroids (Nandrolone and Trenbolone). Their metabolites (19-norandrosterone, 19-noretiocholanolone) are detectable for 12 to 18 months after the last dose, and these residual metabolites continue to provide weak but persistent negative feedback on the HPTA, delaying recovery. This is one reason why 19-nor compounds are considered intermediate-to-advanced drugs: the recovery timeline is meaningfully longer and more complex than with testosterone alone.

Aromatisation of testosterone and its derivatives to oestradiol adds another layer of endocrine disruption. Elevated oestradiol drives gynaecomastia (ductal proliferation in breast tissue), water retention (through aldosterone and ADH upregulation), and mood changes. Aromatase inhibitors manage this by reducing oestrogen production, but over-suppression of oestrogen carries its own consequences: joint pain, impaired bone metabolism, cognitive fog, lipid profile deterioration, and loss of libido. The goal is balance, guided by bloodwork, not elimination.

How do steroids affect the liver?

Liver effects are almost exclusively a concern with 17-alpha-alkylated oral steroids, as covered in depth in our oral vs injectable steroids guide. The 17-alpha-alkyl group resists hepatic first-pass metabolism, allowing oral bioavailability but causing the steroid to cycle repeatedly through hepatic tissue before clearance. The result is a cholestatic pattern of injury: impaired bile flow, elevated liver enzymes (ALT, AST, GGT, ALP), and in rare prolonged cases, peliosis hepatis and hepatic adenomas.

Non-alkylated injectable steroids are not hepatotoxic in this direct sense. They are metabolised by the liver gradually as they circulate, without the concentrated first-pass exposure that causes cholestasis. This does not mean the liver is unaffected by injectable cycles: altered lipid metabolism, SHBG production changes, and increased haematocrit all involve hepatic function. But the organ-threatening hepatotoxicity (cholestasis, peliosis, tumours) is specific to 17-alpha-alkylated compounds.

The practical implication is simple: if you use oral steroids, limit duration to four to six weeks, use liver support (TUDCA and NAC), eliminate alcohol completely, and monitor liver enzymes through bloodwork at baseline, mid-cycle, and post-cycle.

How do steroids affect the brain and mood?

The neuropsychiatric effects of anabolic steroids are among the most noticeable to users and the people around them, yet they remain the least well understood mechanistically. What is clear from a 2018 review in Molecular Neurobiology is that two distinct neural pathways are involved, each producing different behavioural changes.

The direct pathway operates through the amygdalo-fugal tract, connecting the central nucleus of the amygdala to the brainstem. Chronic androgen exposure modifies this pathway in ways that alter cognitive-emotive processing, increasing anxiety and hypervigilance. This is the mechanism behind the restlessness, irritability, and sleep disruption that many users report, particularly on compounds with strong central nervous system penetration like Trenbolone.

The indirect pathway operates through neurotransmitter systems in the latero-anterior hypothalamus. Anabolic steroids modify serotonergic (5-HT), dopaminergic, and GABAergic signalling in brain regions that regulate aggression, mood, reward, and sexual behaviour. Specifically, chronic AAS exposure downregulates 5-HT receptor expression in the prefrontal cortex and amygdala, which reduces serotonergic inhibition of impulsive and aggressive behaviour. This is the neurochemical basis of what users call “roid rage,” though the reality is more nuanced than that phrase suggests: a 2019 literature review found that mood disorders were present in approximately 22% of AAS users, meaning the majority do not experience clinically significant mood disruption.

The dose and compound matter enormously. At moderate testosterone doses (300mg to 500mg per week), mood effects are typically positive: increased confidence, motivation, libido, and assertiveness. At higher doses and with more androgenic compounds (Trenbolone, Halotestin), the probability of anxiety, irritability, aggression, and sleep disruption increases substantially. Nandrolone has its own distinctive neuropsychiatric profile, with some users reporting depression and emotional blunting, which may relate to its interaction with the progesterone receptor and its effects on dopaminergic signalling.

The post-cycle period deserves special mention. When exogenous androgens are discontinued and endogenous production has not yet recovered, users enter a period of low testosterone that can produce genuine depressive symptoms: low mood, anhedonia, fatigue, irritability, and loss of motivation. This is not psychological; it is the neurochemical consequence of hypogonadism. Effective PCT shortens this period, but it is a predictable part of the cycle that users should be prepared for.

How do steroids affect the skin?

Dermatological effects are mediated by androgenic activity at the sebaceous glands and hair follicles, both of which express androgen receptors at high density. Supraphysiological androgen levels stimulate sebaceous gland hypertrophy and increase sebum production, which creates the oily, acne-prone skin that many steroid users experience. The acne is typically worst on the back, shoulders, and chest (areas with the highest sebaceous gland density) and tends to resolve after the cycle ends, though severe cases can cause scarring.

Androgenic alopecia (male pattern hair loss) is accelerated by steroids in genetically susceptible individuals. The mechanism involves DHT (or other androgens) binding to receptors in the dermal papilla of hair follicles, triggering a miniaturisation process that progressively shrinks the follicle until it can no longer produce a visible hair. Compounds that are converted to DHT by 5-alpha reductase (testosterone) or that are already DHT derivatives (Winstrol, Masteron, Proviron) carry the highest risk. Compounds that are converted to weaker metabolites in the scalp (Nandrolone) or that have low androgenic ratings (Anavar) are less likely to accelerate hair loss. A detailed analysis is in our Anavar hair loss guide.

How do steroids affect the reproductive system?

In men, the reproductive effects are a direct consequence of HPTA suppression. LH and FSH drop to near zero on cycle, which shuts down both testosterone production and spermatogenesis. Testicular volume decreases measurably (typically by 20% to 40% during a standard cycle) because the Leydig and Sertoli cells atrophy in the absence of gonadotropin stimulation. Sperm count drops, often to azoospermia (zero sperm) within 8 to 12 weeks of initiating a cycle. For men who want to preserve fertility, HCG administered during the cycle (250 to 500 IU twice weekly) maintains intratesticular testosterone and Leydig cell function, preventing the worst of the testicular atrophy and supporting ongoing spermatogenesis.

Recovery of spermatogenesis after discontinuation is usually complete but slow. Studies of male contraceptive trials using exogenous testosterone found that most men recover to baseline sperm counts within 6 to 12 months after cessation, though individual timelines vary considerably. A minority of long-term users (particularly those who have cycled continuously for years or used high-dose 19-nor compounds) may experience persistent oligospermia or azoospermia that does not fully resolve, requiring fertility treatment if conception is desired.

In women, exogenous androgens produce virilisation: deepening of the voice, clitoral enlargement, menstrual irregularity, increased body hair, and facial hair growth. Some of these changes (particularly voice deepening and clitoral enlargement) are irreversible once established, which is why female steroid use requires extremely careful compound and dose selection. Anavar at 5mg to 10mg daily is the compound most commonly used by women because its low androgenic rating minimises virilisation risk at appropriate doses.

How do steroids affect the kidneys?

The kidneys are affected primarily through indirect mechanisms rather than direct toxicity. Elevated blood pressure on cycle increases the workload on renal vasculature. Increased haematocrit raises blood viscosity, which affects renal blood flow. And the kidneys are responsible for excreting many steroid metabolites, increasing their metabolic burden during heavy use.

Focal segmental glomerulosclerosis (FSGS) has been reported in case studies of long-term AAS users, though the mechanism is debated: it may be related to the hypertension, the direct effects of androgens on renal tissue, or the combination of both with the extremely high protein intakes typical of bodybuilding diets. For most users running standard cycles with controlled blood pressure, the kidneys are not a primary concern. For long-term users or those with pre-existing renal conditions, kidney function monitoring (creatinine, eGFR, urine protein) should be part of regular bloodwork. Our Anavar kidney damage guide covers the cystatin C confound that makes renal monitoring more complex for steroid users.

What reverses after stopping and what might not?

Most effects of anabolic steroids are reversible after discontinuation. Liver enzymes normalise within weeks. Lipid profiles recover within 6 to 10 weeks. Haematocrit returns to baseline. Blood pressure drops. Testicular volume recovers. Acne resolves. Mood returns to baseline once endogenous testosterone recovers. Left ventricular hypertrophy reverses substantially (though not always completely) over months to a year.

The effects that may not fully reverse are: atherosclerotic plaque accumulation (plaque does not regress significantly once deposited), myocardial fibrosis (if it develops during prolonged heavy use), hair follicle miniaturisation in genetically susceptible individuals (lost follicles do not regenerate), voice deepening in women, and persistent hypogonadism in a minority of long-term male users whose HPTA does not fully recover.

The single most effective strategy for minimising irreversible damage is limiting the total duration of lifetime steroid exposure: shorter cycles, adequate time off between cycles (confirmed by bloodwork showing full recovery), and the minimum effective dose. Longer exposure, higher doses, and more compounds all increase the cumulative risk, and some of that risk is permanent. For independently verified compounds, Hemi Pharma publishes all Janoshik lab results before sale.

Frequently Asked Questions

What is the most dangerous side effect of steroids?

Cardiovascular disease is the most significant long-term health risk of anabolic steroid use. The combination of atherogenic dyslipidaemia, left ventricular hypertrophy, elevated haematocrit, hypertension and prothrombotic changes creates a cumulative cardiovascular risk that increases with duration and intensity of use. Acute events (myocardial infarction, stroke, pulmonary embolism) are rare but have been documented in relatively young steroid users, particularly those with unmonitored blood pressure and haematocrit. Regular bloodwork and blood pressure monitoring substantially reduce this risk.

Do all steroids cause the same side effects?

No. Side effect profiles vary significantly between compounds based on their metabolic fate and receptor interactions. Steroids that aromatise to oestrogen (testosterone, Dianabol) cause water retention and gynaecomastia risk. Steroids that are strong androgens or convert to DHT (Winstrol, Masteron, Proviron) cause more acne and hair loss. 19-nor compounds (Nandrolone, Trenbolone) produce progesterone-related sides including prolactin elevation and sexual dysfunction. 17-alpha-alkylated orals cause liver stress. Every compound has a distinct risk profile that should inform your choice.

Are steroid side effects permanent?

Most side effects are reversible after discontinuation and appropriate recovery time. Liver enzymes, lipids, haematocrit, blood pressure, testicular volume, acne and mood all normalise. The effects most likely to be permanent are atherosclerotic plaque accumulation, myocardial fibrosis from prolonged heavy use, hair follicle miniaturisation in genetically susceptible men, voice deepening in women, and persistent hypogonadism in a minority of long-term male users.

How can you reduce the health risks of steroid use?

The five most impactful risk-reduction measures are: regular bloodwork (baseline, mid-cycle, post-PCT, and recovery confirmation), home blood pressure monitoring, using the minimum effective dose for the shortest effective duration, allowing full recovery between cycles (confirmed by bloodwork, not just a calendar count), and maintaining cardiovascular exercise throughout the cycle. Ancillaries (aromatase inhibitors, liver support, PCT drugs) manage specific risks but do not eliminate the need for monitoring.

How do steroids affect you mentally?

The mental effects are dose- and compound-dependent. At moderate testosterone doses, most users report improved mood, confidence, motivation and libido. At higher doses and with more androgenic compounds, a subset of users (approximately 22% based on available data) experience clinically significant mood disruption including anxiety, irritability, aggression and sleep disturbance. The post-cycle period typically produces temporary depressive symptoms due to low testosterone during HPTA recovery. Compounds with strong CNS penetration (Trenbolone in particular) carry the highest neuropsychiatric risk.

References

Kalogeropoulos AP, et al. Impact of anabolic-androgenic steroid abuse on the cardiovascular system: molecular mechanisms and clinical implications. J Clin Med. 2025;14(13):4541. PMC12652398

Rasmussen JJ, et al. Cardiovascular disease in anabolic androgenic steroid users. Circulation. 2024;150(21):1655-1664. doi:10.1161/CIRCULATIONAHA.124.071117

Bertozzi G, Sessa F, Maglietta F, et al. The role of anabolic androgenic steroids in disruption of the physiological function in discrete areas of the central nervous system. Mol Neurobiol. 2018;55(7):5548-5556. PMC5994209

Torrisi M, Pennisi G, Russo I, et al. Neuropsychiatric and behavioral involvement in AAS abusers: a literature review. Medicina. 2019;55(7):396. PMC6681542

Smit DL, Voogel AJ, den Heijer M, de Ronde W. Anabolic androgenic steroids induce reversible left ventricular hypertrophy and cardiac dysfunction: echocardiography results of the HAARLEM study. Front Reprod Health. 2021;3:732318. PMC9580689

Shopping Basket
Scroll to Top